Lirilumab With Rituximab for Relapsed, Refractory or High-risk Untreated Chronic Lymphocytic Leukemia (CLL) Patients

NCT02481297 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

7

Enrollment

OTHER

Sponsor class

Conditions

Leukemia
Chronic Lymphocytic Leukemia
Lymphocytic Leukemia

Interventions

DRUG: Lirilumab
DRUG: Rituximab

Sponsor

M.D. Anderson Cancer Center

Collaborators

[object Object]